Zim Laboratories Receives Approval for Naproxen Delayed Release and Esomeprazole Capsules from CDSCO

Zim Laboratories Limited, a research-driven pharmaceutical company, has received permission from the Indian Central Drugs Standard Control Organization (CDSCO) for its novel Fixed Dose Combination formulation: Naproxen Delayed Release and Esomeprazole Capsules (375 mg/500 mg + 20 mg/20 mg). This product has been developed using ZIM’s proprietary drug delivery systems, offering a differentiated and patient-friendly delivery platform. The FDC is indicated in adults for symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and reducing the risk of NSAID-associated gastric and duodenal ulcers. This approval strengthens ZIM’s presence in the pain management and gastro-protective therapeutic areas and reinforces ZIM’s strategy of developing innovative, differentiated generics leveraging advanced formulation technologies.